Lisa Bodei

Lisa Bodei is a world authority on peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors, having contributed to the NETTER-1 trial that demonstrated Lu-177 DOTATATE (Lutathera) significantly improves progression-free survival in midgut neuroendocrine tumors, leading to FDA approval. Her expertise in dosimetry-based treatment planning has established methods for personalizing PRRT dosing to maximize tumor-absorbed dose while protecting kidneys and bone marrow. She has extended PRRT approaches to additional somatostatin receptor-positive tumor types and is investigating combination strategies with targeted therapies. Her clinical research has defined the safety profile and long-term outcomes of radioligand therapy in neuroendocrine tumors.